asciminib cml
asciminib cml
# Authors
[Author names will be added]
Background: This study investigates asciminib cml.
Methods: A retrospective/prospective analysis was conducted.
Results: Key findings demonstrate significant associations.
Conclusion: These results suggest important clinical implications.
Keywords: [To be added]
# Introduction
asciminib cml represents an important area of investigation in hematology.
## Background
The pathogenesis and treatment of hematological malignancies have evolved significantly in recent years.
## Rationale
This study builds upon recent advances including:
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. (2024)
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. (2024)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. (2019)
## Objectives
This study aims to investigate asciminib cml and provide insights into its clinical relevance.
# Methods
## Study Design
This was a observational study conducted to investigate the research objectives.
## Patients
Patients were enrolled according to predefined inclusion and exclusion criteria:
Inclusion criteria will be specified
Exclusion criteria will be specified
## Data Collection
Data were collected from medical records following institutional protocols.
## Statistical Analysis
Statistical analysis was performed using appropriate software.
Continuous variables were compared using parametric/non-parametric tests.
Categorical variables were analyzed using chi-square or Fisher's exact test.
Survival analysis was conducted using Kaplan-Meier method.
P-value < 0.05 was considered statistically significant.
# Results
## Patient Characteristics
A total of [N] patients were included in this analysis of asciminib cml.
## Clinical Outcomes
The primary endpoints were assessed as follows:
Primary endpoint 1: [result]
Primary endpoint 2: [result]
## Survival Analysis
Overall survival and progression-free survival were evaluated.
## Subgroup Analysis
Predefined subgroup analyses were conducted.
# Discussion
## Principal Findings
This study provides insights into asciminib cml.
The results demonstrate [key findings].
## Comparison with Existing Literature
Our findings are consistent with/extend previous observations.
## Clinical Implications
These results have important implications for clinical practice.
## Strengths and Limitations
This study has several strengths including [strengths].
However, limitations should be acknowledged:
Retrospective design
Single-center experience
Potential selection bias
## Future Directions
Larger prospective studies are needed to validate these findings.
# Authors' Contributions
[To be specified]
# Conflict of Interest
The authors declare no conflicts of interest.
# Acknowledgments
[To be added]
# References
[1] Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, et al.. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.. The New England journal of medicine. 2024;391(10). doi:10.1056/NEJMoa2400858
[2] Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.. American journal of hematology. 2024;99(11). doi:10.1002/ajh.27443
[3] Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, et al.. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.. The New England journal of medicine. 2019;381(24). doi:10.1056/NEJMoa1902328
[4] Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.. American journal of hematology. 2022;97(9). doi:10.1002/ajh.26642
[5] Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, et al.. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.. Leukemia. 2023;37(3). doi:10.1038/s41375-023-01829-9
[6] Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, et al.. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.. Blood. 2021;138(21). doi:10.1182/blood.2020009984
[7] Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, et al.. Management of chronic myeloid leukemia in 2023 - common ground and common sense.. Blood cancer journal. 2023;13(1). doi:10.1038/s41408-023-00823-9
[8] Jabbour E, Kantarjian H. Chronic Myeloid Leukemia: A Review.. JAMA. 2025;333(18). doi:10.1001/jama.2025.0220
[9] Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, et al.. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.. Blood. 2024;144(19). doi:10.1182/blood.2024024657
[10] Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.. Leukemia research. 2020;98. doi:10.1016/j.leukres.2020.106458
[11] Cortes JE, Hochhaus A, Takahashi N, Larson RA, Issa GC, et al.. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.. Future oncology (London, England). 2022;18(38). doi:10.2217/fon-2022-0923
[12] Atallah EL, Mauro MJ, Sasaki K, Levy MY, Koller P, et al.. Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.. Future oncology (London, England). 2024;20(38). doi:10.1080/14796694.2024.2402680
[13] Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, et al.. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.. Leukemia. 2024;38(7). doi:10.1038/s41375-024-02278-8
[14] Costa A, Scalzulli E, Bisegna ML, Breccia M. Asciminib in the treatment of chronic myeloid leukemia in chronic phase.. Future oncology (London, England). 2025;21(7). doi:10.1080/14796694.2025.2464494
[15] Takahashi N, Kikushige Y, Nakamae H, Goto T, Tomita A, et al.. Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.. International journal of hematology. 2025;122(5). doi:10.1007/s12185-025-04014-z